WMSA
CTMX icon

Weiss Multi-Strategy Advisers’s CytomX Therapeutics CTMX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,000
Closed -$229K – 542
2018
Q2 		$229K Buy
+10,000
New +$255K 0.01% 518

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Weiss Multi-Strategy Advisers's CTMX Position: Q3 2018 in Review

Weiss Multi-Strategy Advisers sold out of CytomX Therapeutics (CTMX) in Q3 2018, closing a stake of 10,000 shares — an estimated $229K sold.

Weiss Multi-Strategy Advisers first reported a position in CTMX in Q2 2018 and held it in 1 quarter. The position peaked at $229K in Q2 2018. 122 funds tracked by Wall St. Rank hold CTMX as of Q3 2018.

  • Weiss Multi-Strategy Advisers reported no remaining CytomX Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 10,000 CytomX Therapeutics shares in Q3 2018, an estimated $229K.
  • Weiss Multi-Strategy Advisers first reported a position in CytomX Therapeutics in Q2 2018 and held it in 1 quarter.
  • Weiss Multi-Strategy Advisers's CytomX Therapeutics position peaked at $229K in Q2 2018.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2018.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.